Download PDF
Hamostaseologie 1993; 13(03): 132-137
DOI: 10.1055/s-0038-1655226
Übersichtsarbeiten/Review Articles
Schattauer GmbH

Das Trousseausche Syndrom

Ein paraneoplastisches Phänomen
Bettina Kemkes-Matthes
1   Zentrum für Innere Medizin der Universität Gießen (Direktor: Prof. Dr. Dr. h. c. mult. H. G. Lasch)
› Author Affiliations
Further Information

Publication History

Publication Date:
26 June 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Patienten mit malignen Erkrankungen leiden gehäuft unter thromboembolischen Komplikationen. Die Ätiologie dieser Komplikationen ist vielfältig und hängt sowohl von Art und Ausbreitung des Tumors, dem Ausmaß der begleitenden Akute-Phase-Reaktion als auch vom Vorliegen zusätzlicher Risikofaktoren ab: Das Zusammenspiel von Strömungsveränderungen, Endothelaktivierung unter dem Einfluß von Zytokinen und Aktivierung der Gerinnungskaskade durch »Cancer Procoagulants« oder Tissue-Faktor-ähnliche Substanzen bei gleichzeitiger Verminderung von Gerinnungsinhibitoren und fibrinolytischem Potential begünstigt das Auftreten thrombembolischer Komplikationen.

Schlüsselwörter

Paraneoplastisches Syndrom - Thrombose - Krebs - Gerinnungsaktivierung
 

  • LITERATUR

  • 1 Sack GH, Levin J, Bell W. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiological, and therapeutic features. Medicine 1977; 56 (01) 1-37.
    CrossrefPubMedGoogle Scholar
  • 2 Trousseau A. Phlegmasia alba dolens. Clin Med Hotel Dieu de Paris 1865; 03: 94.
    PubMedGoogle Scholar
  • 3 Sun NC, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. I. Coagulation studies. Am J Clin Pathol 1979; 71: 10-6.
    CrossrefPubMedGoogle Scholar
  • 4 Ambrus JL, Ambrus CM, Mink IB, Pickren JW. Causes of death in cancer patients. J Med 1975; 06: 61-4.
    PubMedGoogle Scholar
  • 5 Sproulw EE. Carcinoma and venous thrombosis : The frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 1938; 24: 566-85.
    PubMedGoogle Scholar
  • 6 Anylan WG, Shingleton WW, Delaughter Jr GD. Significance of idiopathic venous thrombosis and hidden cancer. J Am Med Ass 1956; 161: 964-70.
    CrossrefPubMedGoogle Scholar
  • 7 Hoerr SO, Harper JR. Clinical notes on peripheral thrombophlebitis. J Am Med Ass 1957; 164: 2033-44.
    CrossrefPubMedGoogle Scholar
  • 8 Soong BCF, Miller SO. Coagulation disorders in cancer. III. Fibrinolysis and inhibition. Cancer 1970; 25: 867-73.
    CrossrefPubMedGoogle Scholar
  • 9 Liebermann JS, Borrero J, Urdanetta E, Wright IS. Thrombophlebitis and cancer. J Am Med Ass 1961; 177: 542-5.
    CrossrefPubMedGoogle Scholar
  • 10 Quintela Gonzalez, Candela MJ, Vidal C, Roman J, Aramburo P. Non-bacterial thrombotic endocarditis in cancer patients. Acta Cardiol 1991; XLVI (01) 1-9.
    PubMedGoogle Scholar
  • 11 Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau’s syndrome revised. Blood 1983; 62 (01) 14-31.
    PubMedGoogle Scholar
  • 12 Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MB, Hryniuk W, De Pauw S. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318: 404-7.
    CrossrefPubMedGoogle Scholar
  • 13 Weess RB, Tormey DC, Holland JF, Weinberg VE. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep 1981; 65: 677-9.
    PubMedGoogle Scholar
  • 14 Kasimis BS, Spiers AD. Thrombotic complications in patients with advanced prostatic cancer treated with chemotherapy. Lancet 1979; I: 159.
    PubMedGoogle Scholar
  • 15 Virchow R. Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Frankfurt: Meidiger Sohn; 1856: 477.
    Google Scholar
  • 16 Bulas DI, Thompson R, Reaman G. Pulmonary emboli as a primary manifestation of Wilms tumor. Am J Roentgenol 1991; 156: 155-6.
    CrossrefPubMedGoogle Scholar
  • 17 Patterson WP, Caldwell CW, Doll DC. Hyperviscosity syndromes and coagulopathies. Semin Oncol 1990; 17 (02) 210-6.
    PubMedGoogle Scholar
  • 18 Edwards RL, Rickies FR, Moritz TE, Henderson WG, Zacharski LR, Forman WB, Cornell CJ, Forcier RJ, O’Donnell JF, Headley E, Kin S-H, O’Dell R, Tornyos K, Kwaan HC. Abnormalities of blood coagulation tests of patients with cancer. Am J Clin Pathol 1987; 88 (05) 596-602.
    CrossrefPubMedGoogle Scholar
  • 19 Castell JV, Gömez-Lechön MJ, David M, Hirano T, Kishimoto T, Heinrich PC. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Letters 1988; 232 (02) 347-50.
    CrossrefPubMedGoogle Scholar
  • 20 Andus T, Geiger T, Hirano T, Kishimoto T, Tran-Thi T-A, Decker K, Heinrich PC. Regulation of synthesis and secretion of major rat acute-phase proteins by recombinant human interleukin-6 (BSF-2/IL-6) in hepatocyte primary cultures. Eur J Biochem 1988; 173: 287-93.
    CrossrefPubMedGoogle Scholar
  • 21 Castell JV, Gömez-Lechön MJ, David M, Andus T, Geiger T, Trullenque R, Fabra R, Heinrich PC. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Letters 1989; 242 (02) 237-9.
    CrossrefPubMedGoogle Scholar
  • 22 Brazel D, Seiler FR. Struktur und Biologie von Interleukinen. Hämostaseologie 1990; 10: 52-63.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Balkwill F, Osborne R, Burke F, Naylor S, Talbot D, Durbin H, Tavernier J, Fiers W. Evidence for tumor necrosis factor/cachectin production in cancer. Lancet 1987; II: 1229-32.
    PubMedGoogle Scholar
  • 24 Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989; 73 (01) 159-65.
    PubMedGoogle Scholar
  • 25 Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA. Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exper Med 1984; 160: 618-23.
    CrossrefPubMedGoogle Scholar
  • 26 van Hinsbergh VWM, Kooistra T, van den Berg EA, Princen HGM, Fiers W, Emeis JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988; 72 (05) 1467-73.
    PubMedGoogle Scholar
  • 27 Zacharski LR, Wojtukiewicz MZ, Constantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Sem Thromb Hemostas 1992; 18 (01) 104-16.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Zacharski LR, Howell AL, Memoli VA. The coagulation biology of cancer. Fibrinolysis 1992; 06 (01) 39-42.
    PubMedGoogle Scholar
  • 29 Asherson RA. A »primary« antiphospholipid syndrome?. J Rheumatol 1988; 15 (12) 1742-6.
    PubMedGoogle Scholar
  • 30 Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48 (04) 499-509.
    PubMedGoogle Scholar
  • 31 Feffer SE, Carmosino LS, Fox RL. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer 1989; 63: 1303-7.
    CrossrefPubMedGoogle Scholar
  • 32 Rogers JS, Murgo AJ, Fontana JA, Raich PC. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 1988; 06 (02) 276-81.
    CrossrefPubMedGoogle Scholar
  • 33 Kemkes-Matthes B, Plusczyk T, Lasch HG. Coagulation inhibitors in pulmonary cancer patients. Thromb Res 1992; 65: 85-94.
    CrossrefPubMedGoogle Scholar
  • 34 Kemkes-Matthes B. Acquired protein S deficiency. Clin Invest 1992; 70: 529-34.
    PubMedGoogle Scholar
  • 35 Lindahl K, Sandset PM, Abildgaard U, Andersson TR, Harbitz TB. High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer. Acta Chir Scand 1989; 155: 389-93.
    PubMedGoogle Scholar
  • 36 Nishino N, Aoki K, Tokura Y, Sakaguchi S, Takada Y, Takada A. The urokinase type of plasminogen activator in cancer of digestive tract. Thromb Res 1988; 50: 527-35.
    CrossrefPubMedGoogle Scholar
  • 37 Schneider W, Südhoff T. Fibrinolyse und Tumorkrankheit. Fibrinolyse 1991; 03: 4-9.
    PubMedGoogle Scholar
  • 38 Hart DA. Dysregulation of plasminogen activators in cancer potential role in invasion, metastasis and as prognostic indicator. Fibrinolysis 1992; 06 (01) 11-5.
    PubMedGoogle Scholar
  • 39 Newland JR, Haire WD. Elevated plasminogen activator inhibitor levels found in patients with malignant conditions. Am J Clin Pathol 1991; 96 (05) 602-4.
    CrossrefPubMedGoogle Scholar
  • 40 De Jong E, Knot EAR, Piket D, Iburg AHC, Rijken DC, Veenhoff KHN, Dooijewaard G, ten Cate JW. Increased plasminogen activator inhibition levels in malignancy. Thromb Haemost 1987; 57 (02) 140-3.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Rocha E, Paramo JA, Fernandez FJ, Cuesta B, Hernandez M, Paloma MJ, Rifön J. Clotting activation and impairment of fibrinolysis in malignancy. Thromb Res 1989; 54: 699-707.
    CrossrefPubMedGoogle Scholar
  • 42 Medina R, Socher SH, Han JH, Friedman PA. Interleukin-1, endotoxin or tumor necrosis factor/cachektin enhance the level of plasminogen activator inhibitor messenger RNA in bovine aortic endothelial cells. Thromb Res 1989; 54: 41-52.
    CrossrefPubMedGoogle Scholar
  • 43 Gore JM, Applebaum JS, Greene HL. Occult cancer in patients with acute pulmonary embolism. Ann Intern Med 1982; 96: 556-60.
    CrossrefPubMedGoogle Scholar
  • 44 Goldberg RJ, Seneff M, Gore JM, Anderson Jr FA, Greene HL, Wheeler HB, Dalen JE. Occult malignant neoplasms in patients with deep venous thrombosis. Arch Intern Med 1987; 147: 251-3.
    CrossrefPubMedGoogle Scholar
  • 45 Griffin MR, Stanson PW, Brown ML. Deep venous thrombosis and pulmonary embolism. Risk of subsequent malignant neoplasms. Arch Intern Med 1987; 147: 1907-11.
    CrossrefPubMedGoogle Scholar
  • 46 McKenna MT. Deep venous thrombosis and the risk of cancer. Arch Intern Med 1989; 149: 968-9.
    PubMedGoogle Scholar
  • 47 Luzzato G, Schaefer AI. The prethrombotic state in cancer. Semin Oncology 1990; 17 (02) 147-59.
    PubMedGoogle Scholar